Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) saw its shares jump 20% in pre-market trading today after the biotech firm reported positive data from a trial of a treatment for a form of myasthenia gravis.
The Nasdaq-listed company said the investigator-sponsored trial of its Firdapse drug as a treatment for seven myasthenia gravis patients with anti-MuSK antibodies met its main goals.
The study of patents with the rare neuromuscular disease, for which there is currently no treatment, was conducted in Milan, Italy.
In a statement, Dr Renato Mantegassa, director of the department of neuroimmunology and neuromuscular diseases at the Fondazione Istituto Neurologico Carlo Besta said: “Not only are the results statistically significant, but more importantly, there was a large clinical benefit to the patients.”
Catalyst shares, which have gained 11% so far this year, were up 19.6% at US$1.40.
Story by ProactiveInvestors